Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP, near-guideline, animal experimental study, also published in peer-reviewed literature, minor restrictions in design and reporting but otherwise acceptable for assessment.
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in Section 13 of the dossier.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 982
Materials and methods
Test guideline
- Guideline:
- other: Not specified
- Principles of method if other than guideline:
- Standard method
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 3a,4,7,7a-tetrahydro-4,7-methanoindene
- EC Number:
- 201-052-9
- EC Name:
- 3a,4,7,7a-tetrahydro-4,7-methanoindene
- Cas Number:
- 77-73-6
- Molecular formula:
- C10H12
- IUPAC Name:
- 3a,4,7,7a-tetrahydro-1H-4,7-methanoindene
- Reference substance name:
- dicyclopentadiene (DCPD)
- IUPAC Name:
- dicyclopentadiene (DCPD)
- Details on test material:
- - Name of test material (as cited in study report): DCPD
- Physical state: clear colourles liquid at room temperature
- Analytical purity: Analytical purity: >95% endo-DCPD,0.5% iso-DCPD and ~1% cyclopentadiene (CPD)
Constituent 1
Constituent 2
Test animals
- Species:
- mouse
- Strain:
- other: B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breedign Laboratory, Portage, MI, USA
- Age at study initiation: 30-34 days
- Weight at study initiation: no data
- Fasting period before study: no data
- Housing: Individually in stainless steel wire mesh suspended cages
- Diet: powdered NIH-07 diet ad libitum except during exposure
- Water: ad libitum except during exposure
- Acclimation period: no data
ENVIRONMENTAL CONDITIONS
- Temperature: 68-72°F (70-79°F during exposure)
- Humidity: 40-60% (39-68% during exposure)
- Air changes (per hr): no data
- Photoperiod (12 hrs dark / 12 hrs light):
IN-LIFE DATES: July 1981 - January 1981
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Remarks on MMAD:
- MMAD / GSD: not applicable
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Stainless steel rectangular (2m x 2m x1m) exposure chamber with glass windows and door in front wall (total volume 4350L).
- Method of holding animals in test chamber: individually in suspended stainless steel wire mesh cage with stainless steel pans between each layer of cages to prevent contamination. Cage positions were rotated routinely.
- System of generating particulates/aerosols:DCPD vapour was generated by heating the liquid in a Pyrex tube using a minimum amount of heat to prevent decomposition and formation of CPD. Filtered air was used to dilute the vapour prior to introduction into the chamber.
- Temperature, humidity, pressure in air chamber:
- Air flow rate: 2000 L/min
TEST ATMOSPHERE
- Brief description of analytical method used: Chamber concentrations were analysed at hourly intervals by gas chromatography/flame ionization detection. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Actual concentrations: 0, 1.0, 5.1 and 51 ppm
- Duration of treatment / exposure:
- 13 wks
- Frequency of treatment:
- 6 hr/day, 5 days/wk
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 1, 5, 50 ppm
Basis:
other: Target concentrations
- Remarks:
- Doses / Concentrations:
1, 5.1, 51 ppm
Basis:
analytical conc.
- Remarks:
- Doses / Concentrations:
0, 5, 27.6, 276 mg/m3
Basis:
analytical conc.
- No. of animals per sex per dose:
- 45
- Control animals:
- yes
- Details on study design:
- Post-exposure observation periods of 4 and 13 wks.
Nine mice/sex/dose were scheduled for sacrifice after 2, 6, and 13 wks of exposure and 4 and 13 wks post-exposure.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Mice were observed for clinical signs before and after each exposure, and daily during the recovery period. During exposure mice were observed several times trough the chamber window.
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: Body wt was recorded at initiation, weekly during both the exposure period and the first 5 wks of recovery, and then every 2 wks. Animals were also weighed before termination.
FOOD CONSUMPTION: no
FOOD EFFICIENCY: No data
OPHTHALMOSCOPIC EXAMINATION: Yes
- High dose mice received ophthalmoscopic examination before sacrifice
HAEMATOLOGY: Yes
- Haematology analyses were performed on all mice prior to sacrifice after 2, 6 and 13 wk exposure and 4 and 13 wk post-exposure with blood from the orbital sinus. Erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin and concentration, and total/differential white blood cell counts were determined.
CLINICAL CHEMISTRY: Yes
- Serum chemistry analyses were performed on all mice prior to sacrifice after 2, 6 and 13 wk exposure and 4 and 13 wk post-exposure with blood from the orbital sinus. Serum was analyzed for creatinine, urea nitrogen, calcium, phosphrous, chloride, alanine aminotransferase, aspartate aminotransferase, total protein, albumin, total bilirubin, alkaline phosphatase, glucose and osmolality. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- Necropsies were conducted on all mice.
- Kidneys, lungs, liver and testes were weighed.
- Adrenals, bone and bone marrow (sternum), brain, epididymides, eyes, heart, kidneys, larynx, liver, lungs, lymph nodes (mediastinal), muscle (gastrocnemeous), nasal turbinates, parathyroids, pituitary, sciatic nerve, spleen, testes, thymus, thyroids, trachea, urinary bladder and gross lesions were preserved for microscopic evaluation.
HISTOPATHOLOGY: Yes
- Organs were examined microscopically in control and high dose mice sacrificed after 13 wks of exposure. - Statistics:
- Analysis of variance, Bartlett’s test, Duncan’s multiple range test, F-test, Student’s t-test, Cochran t-test (applied when appropriate).
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- - No significant clinical signs or body wt changes were noted prior to death. The likely cause of death appeared to be pulmonary congestion and possibly renal failure. These effects were not seen in mice sacrificed at the end of the study.
- During exposure, a few of the mice at 51 and 5.1 ppm showed coordination loss and/or decreased activity.
- Mild conjunctivitis was seen in one male mouse at 51ppm. - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Ten males and 9 female mice exposed to 51 ppm DCPD died during the study; whereas no more than 2 mice died at any other level.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Males and females in the 51 ppm group showed significant elevation in body wt gain that returned to control values during recovery.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 5.1 ppm (analytical)
- Sex:
- male/female
- Basis for effect level:
- other: 27.6 mg/m3. No systemic toxicity.
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 51 ppm (analytical)
- Sex:
- male/female
- Basis for effect level:
- other: 276 mg/m3. Based on mortality
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Although there were no overt signs of toxicity, exposure to 51 ppm DCPD vapour resulted in the deaths of approximately 20% of mice (males and females), primarily due to pulmonary congestion. The NOAEC is concluded to be 5.1 ppm (27.6 mg/m3)
- Executive summary:
Groups of 45 male and 45 female B6C3F1 mice were exposed by inhalation, 6 h per day, 5 days/week, for 13 weeks (64 exposures) to DCPD vapour at concentrations of 0 (air control), 1, 5.1 or 51 ppm (analysed controls). Animals were sacrificed after 10, 30 and 64 inhalation exposures and post exposure sacrifices were made at 29 and 92 days following the last exposure. Clinical observations, bodyweights, blood clinical chemistry and haematology, ophthalmology, organ weights and histopathology evaluations were made during the study. There were no overt signs of toxicity but approximately 20% of the mice (both sexes) of the 51 ppm exposure group died during the exposure period, primarily due to pulmonary congestion. Similar lung lesions were not seen in animals sacrificed throughout the study. A significant body weight gain was observed, only in female mice, at 51 ppm in the last weeks of the study. No other biologically significant effects were observed.
The NOAEC is therefore concluded to be 5.1 ppm (27.6 mg/m3).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.